Antibody responses to preS components after immunization of children with low doses of BioHepB

Vaccine

Volumn 20, Issue 1-2, 2001, Pages 92-97

  Madalinski, Kazimierz ^a   Sylvan, Staffan P E ^b   Hellström, Ulla ^b   Mikolajewicz, Jolanta ^a   Zembrzuska Sadkowska, Ewa ^a   Piontek, Elzbieta ^a  

^a CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Children; Hepatitis B vaccine; PreS antigens; Response to third generation vaccine

Indexed keywords

BIOHEPB VACCINE; HEPATITIS B VACCINE; MEMBRANE ANTIGEN; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANTIBODY RESPONSE; ARTICLE; CELL LINE; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; GLYCOSYLATION; HEPATITIS B; HUMAN; IMMUNIZATION; KINETICS; PRIORITY JOURNAL; PROTECTION; SEROCONVERSION;

ANIMALS; ANTIBODY SPECIFICITY; CHILD; CHILD, PRESCHOOL; CHO CELLS; CRICETINAE; CRICETULUS; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; INFANT; PROTEIN PRECURSORS; VACCINATION; VACCINES, SYNTHETIC; VIRUS CULTIVATION;

EID: 0035850954     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00312-7     Document Type: Article

References (34)

1. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study
2. Global programme for control of hepatitis B infection
3. Hepatitis B vaccination and hepatocellular carcinoma in Taiwan
4. Hepatitis B vaccine
5. Vaccination of infants and children against hepatitis B
6. Overview of a 5-year clinical experience with yeast-derived hepatitis B vaccine
7. Functions of hepatitis B surface proteins
8. Antibodies to a synthetic peptide from the preS 120-145 region of the hepatitis B virus envelope are virus-neutralizing
9. Antibodies to synthetic peptides from the preS1 region of the hepatitis B virus (HBV) envelope (env) protein are virus-neutralizing and protective
10. T- and B-cell recognition of hepatitis B viral antigens
11. Human T-cell response to the surface antigen of hepatitis B virus (HBsAg)
12. The preS1 antigen of hepatitis B virus is highly immunogenic at the T-cell level in man
13. A synthetic peptide vaccine involving the product of the preS2 region of hepatitis B virus DNA: Protective efficacy in chimpanzees
14. Randomized dose range study of a recombinant hepatitis B vaccine produced in mammalian cells and containing the S and preS2 sequences
15. Recombinant DNA hepatitis B vaccine containing preS components of the HBV coat protein: A preliminary study on immunogenicity
16. Immunogenicity of a mammalian cell-derived recombinant hepatitis B vaccine containing preS2 and preS1 antigens: A preliminary report
17. T-cell and antibody response characterization of a new recombinant preS-1, preS-2 and SHBs antigen-containing hepatitis B vaccine; demonstration of superior anti-SHBs antibody induction in responder mice
18. Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing preS1 and preS2 antigens in neonates
19. Rapid seroprotection against hepatitis B following the first dose of a preS1/preS2/S vaccine
20. Significance of preS2 peptide of hepatitis B virus: Should it be in the vaccine?
21. IgG antibodies to synthetic peptides mimicking B-cell epitopes within the hepatitis B virus (HBV) envelope preS2 region protein: Relation to viremia and liver-disease activity in chronic HBV infection
22. Weak immunogenicity of the preS2 sequence and lack of circumventing effect on the unresponsiveness to the hepatitis B virus vaccine
23. Immunogenicity of a recombinant preS2-containing hepatitis B vaccine versus plasma-derived vaccine administered as a booster
24. Safety and efficacy of a recombinant yeast-derived preS2 + S-containing hepatitis B vaccine (TGP-943): Phases 1, 2 and 3 clinical testing
25. Protective efficacy of a novel hepatitis B vaccine consisting of M (preS2+S) protein particles (a third-generation vaccine)
26. Genetic prediction of non-response to hepatitis B vaccine
27. Relationship between the reactivity to hepatitis B virus vaccination and the frequency of MHC class I, II and III alleles in hemodialysis patients
28. Contribution of human leucocyte antigens to the antibody response to hepatitis B vaccination
29. Analysis of the preS2 N- and O-linked glycans of the M surface protein from human hepatitis B virus
30. Mapping of immunodominant B-cell epitopes and the human serum albumin-binding site in natural hepatitis B virus surface antigen of defined genosubtype
31. Dissociated antibody responses to the S and preS2 regions of the hepatitis B virus after vaccination in hemophiliacs
32. Hepatitis B vaccination in diabetic patients. Randomized trial comparing recombinant vaccines containing and not containing preS2 antigen
33. Clinical experience with a new recombinant hepatitis-B vaccine in previous non-responders with chronic renal insufficiency
34. Immune response to a new hepatitis B vaccine in health-care workers who had not responded to standard vaccine: Randomized double-blind dose-response study